 | | Vol. 13.24 – 21 October, 2022 |
| |
|
|
| Scientists performed the first study integrating whole-genome 5-hydroxymethylcytosine with DNA, 5-methylcytosine, and transcriptome sequencing in clinical samples of benign, localized, and advanced prostate cancer.
[Cancer Research] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| By promoting GATA2 degradation, constitutive photomorphogenesis protein 1 inhibited androgen receptor expression and activation, and repressed prostate cancer cell and xenograft growth and castration resistance.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers observed low SLC22A3 expression and high levels of TAZ or YAP1 in metastatic castration-resistant prostate cancer patient tissues harboring androgen receptor splice variant 7.
[The FEBS Journal] |
|
|
|
| Investigators developed a novel bioengineered BERA-Wnt5a siRNA construct and demonstrated that inhibition of Wnt5a expression by the BERA-Wnt5a siRNA significantly suppressed tumor growth and enhanced enzalutamide treatment in vivo.
[Molecular Cancer Therapeutics] |
|
|
|
| The authors evaluated the phenotypic and functional consequences of short-term, low-level stimulation of adipose-derived mesenchymal stromal cells with Toll-like receptor 3 and 4 agonists.
[Cytotherapy] |
|
|
|
| Researchers tested Paired basic Amino Acid-Cleaving Enzyme 4 (PACE 4) inhibition on JHU-LNCaP-SM, a newly described androgen-independent model, in cell-based and xenograft assays.
[Scientific Reports] |
|
|
|
| Scientists selected two androgen receptor (AR)-interacting RNA splicing factors, Src associated in mitosis of 68 kDa and DEAD box helicase 5 to examine their associative roles in AR-dependent alternative RNA splicing.
[Asian Journal of Andrology] |
|
|
|
|
| The authors review the literature to identify research on the pathobiology of prostate cancer induced bone pain. Additionally, they review clinical trials of various treatment modalities in patients with prostate cancer induced bone pain with pain response outcomes.
[Discover Oncology] |
|
|
|
|
| A three-year, $750,000 grant from the Kleberg Foundation will allow Dr. John Lee and Fred Hutch collaborators Drs. Pete Nelson and Roland Strong to explore curative treatment options for prostate cancer, specifically through the use of immunotherapy.
[Fred Hutchinson Cancer Center] |
|
|
|
| Promontory Therapeutics Inc. announced the US Patent and Trademark Office has issued a patent covering therapeutic applications of its lead compound, PT-112, as an immuno-modulatory agent.
[Promontory Therapeutics Inc.] |
|
|
|
|
| February 5 – 8, 2023
Keystone, Colorado, United States |
|
|
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Merck & Co., Inc. – North Wales, Pennsylvania, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
